Mark J. Gergen
2016 - Halozyme Therapeutics
In 2016, Mark J. Gergen earned a total compensation of $2.2M as Senior Vice President and Chief Operating Officer at Halozyme Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $75,000 |
|---|---|
| Option Awards | $2,002,405 |
| Salary | $145,000 |
| Other | $2,529 |
| Total | $2,224,934 |
Gergen received $2M in option awards, accounting for 90% of the total pay in 2016.
Gergen also received $75K in non-equity incentive plan, $145K in salary and $2.5K in other compensation.
Rankings
In 2016, Mark J. Gergen's compensation ranked 4,401st out of 14,075 executives tracked by ExecPay. In other words, Gergen earned more than 68.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,401 out of 14,075 | 69th |
Division Manufacturing | 1,547 out of 5,489 | 72nd |
Major group Chemicals And Allied Products | 467 out of 1,895 | 75th |
Industry group Drugs | 339 out of 1,538 | 78th |
Industry Biological Products, Except Diagnostic Substances | 64 out of 279 | 77th |
Source: SEC filing on March 24, 2017.
Gergen's colleagues
We found four more compensation records of executives who worked with Mark J. Gergen at Halozyme Therapeutics in 2016.